Drug intelligence / Profile preview

Anadolu Univ. STAT3 compound 2r

Development stage: Unknown
Lead developer: Anadolu University

Overview

Anadolu Univ. STAT3 compound 2r: sourced facts only. name: "Compound 2r was identified as the most potent STAT3 inhibitor, exerting 10.8-fold higher activity than C188-9." [PMID:42612271]; target: "Compound 2r was identified as the most potent STAT3 inhibitor, exerting 10.8-fold higher activity than C188-9." [PMID:42612271]; developer: "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, 26470 Eskişehir, Turkey." [PMID:42612271]

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on Anadolu Univ. STAT3 compound 2r.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anadolu Univ. STAT3 compound 2r.